# Allergy Therapeutics report robust sales growth over challenging period

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-report-robust-sales-growth-over-challenging-period/412952676
- Published: 2021-01-13T07:27:12+00:00
- Author: Giles

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated commercial biotechnology company specialising in allergy vaccines,
has today provided a trading update for the six months ended 31 December 2020 ahead
of its Half Year Results to be announced on 3 March 2021.

–     _Robust sales growth over challenging period_

–     _Record cash position_

–     _Initial Grass MATA MPL Phase III trial progressing well_

–     _Encouraging trial results for ImmunoBON which will be launched in Germany
in January_

**Financials**

The Group is trading in line with Board expectations, with reported revenues for
the six months ended 31 December 2020 having grown to £54.0m (2019: £50.5m), representing
7% growth on a reported basis ( 5% on constant currency basis), despite the challenges
of COVID-19. Geographically, there was growth across most major countries with the
best performances in Germany, Austria, Netherlands and Switzerland. Sales of Pollinex
Quattro and Pollinex continued to progress well, driven by superior technology and
a strong sales and marketing team.

The Group has continued to generate good cash conversion, with a record cash balance
at the end of December 2020 of £48.3m (31 December 2019: £39.7m).

On current internal assumptions, the Group will be able to fund the Grass MATA MPL
Phase III trials, as well as the peanut allergy vaccine candidate Phase I trial,
from existing resources.

**Regulatory**

The Group is progressing well with recruitment and treatment of patients in the 
exploratory field study (G309) of the Grass MATA MPL development programme, which
began in October 2020 and is being executed in the USA and the EU. The design of
this development programme supports a phased Phase III approach (as communicated
in November 2019) and incorporates the lessons learned from previous trials. Results
from the exploratory field study are expected in the autumn of 2021.

The results of a successful allergy trial in a challenge chamber for ImmunoBon, 
our protein-based oral product for the general treatment of allergies which we acquired
exclusive rights to in 2020, were published in the World Allergy Organisation Journal
^(1) earlier this month. These show a significant improvement compared to baseline,
while maintaining an excellent safety and tolerability profile. The product will
be launched in Germany in January 2021.

Finally, as announced earlier this month, the _ex-vivo_ study with VLP Peanut, evaluating
an innovative panel of biomarkers using blood samples from peanut allergic patients
has started, in collaboration with Imperial College London. The results of this 
study are expected in the spring of 2021.

**Board**

After 17 years, Steve Smith has stated his intention to step down as a Non-Executive
Director at the AGM in November. Steve has played a pivotal and very successful 
role in the development of the business over the years and his valued contribution
will be missed.

> **Manuel Llobet, CEO at Allergy Therapeutics, stated:** “The trading results for
> the first six months of the year reflect the robust growth by the business despite
> the continuing challenges of COVID-19. This shows the strength of the business
> and commitment of our staff. Our research and development strategy is developing
> well, with excellent progress in our Grass MATA MPL Phase III development programme,
> the initiation of the ex-vivo peanut study and strong results from the ImmunoBON
> challenge chamber trial. We have much to look forward to in the calendar year 
> 2021, with the submission of the Investigational new Drug Application for our 
> peanut allergy vaccine candidate and results from the Grass exploratory field 
> study.”

> **Peter Jensen, Chairman at Allergy Therapeutics, stated: **“I would like to thank
> Steve Smith for his commitment, wise counsel and attention to detail, during his
> long tenure on the Board of Allergy Therapeutics. Steve joined the Board when 
> the company floated in 2004 and his contribution over the last 17 years has been
> outstanding.”

^(1 )World Allergy Organisation Journal, January 2021

Share on:
